Metabolomics

Dataset Information

0

Clinical efficacy of Yiqi Yangxue formula on knee osteoarthritis and unraveling therapeutic mechanism through plasma metabolites in rats


ABSTRACT:

OBJECTIVE: To observe the clinical efficacy and safety of Yiqi Yangxue formula (YQYXF) on knee osteoarthritis (KOA), and to explore the underlying therapeutic mechanism of YQYXF through endogenous differential metabolites and their related metabolic pathways.

METHODS: A total of 61 KOA patients were recruited and divided into the treatment group (YQYXF, 30 cases) and the control group (celecoxib, Cxb, 31 cases). Effects of these two drugs on joint pain, swelling, erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP) were observed, and their safety and adverse reactions were investigated. In animal experiments, 63 SD rats were randomly divided into normal control (NC) group, sham operation (sham) group, model (KOA) group, Cxb group, as well as low-dose (YL), medium-dose (YM), and high-dose groups of YQYXF (YH). The KOA rat model was established using a modified Hulth method. Ultra-high-performance liquid chromatography/Q Exactive HF-X Hybrid Quadrupole-Orbitrap Mass (UHPLC-QE-MS)-based metabolomics technology was used to analyze the changes of metabolites in plasma samples of rats. Comprehensive (VIP) > 1 and t-test p < 0.05 conditions were used to screen the disease biomarkers of KOA, and the underlying mechanisms of YQYXF were explored through metabolic pathway enrichment analysis. The related markers of YQYXF were further verified by ELISA (enzyme-linked immunosorbent assay).

RESULTS: YQYXF can improve joint pain, swelling, range of motion, joint function, Michel Lequesen index of severity for osteoarthritis (ISOA) score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, ESR, and CRP. No apparent adverse reactions were reported. In addition, YQYXF can improve cartilage damage in KOA rats, reverse the abnormal changes of 16 different metabolites, and exert an anti-KOA effect mainly through five metabolic pathways. The levels of reactive oxygen species (ROS) and glutathione (GSH) were significantly decreased after the treatment of YQYXF.

CONCLUSION: YQYXF can significantly improve the clinical symptoms of KOA patients without obvious adverse reactions. It mainly improved KOA through modulating lipid metabolism-related biomarkers, reducing lipid peroxidation and oxidative stress.

INSTRUMENT(S): Liquid Chromatography MS - positive, Liquid Chromatography MS - negative

SUBMITTER: Fanying Meng 

PROVIDER: MTBLS5667 | MetaboLights | 2024-03-25

REPOSITORIES: MetaboLights

Dataset's files

Source:
Action DRS
MTBLS5667 Other
FILES Other
a_MTBLS5667_LC-MS_negative__metabolite_profiling.txt Txt
a_MTBLS5667_LC-MS_positive__metabolite_profiling.txt Txt
i_Investigation.txt Txt
Items per page:
1 - 5 of 8
altmetric image

Publications

Clinical efficacy of Yiqi Yangxue formula on knee osteoarthritis and unraveling therapeutic mechanism through plasma metabolites in rats.

Zhao Ting T   Wang Shiqi S   Liu Wenbin W   Shen Jiayan J   Dai Youwu Y   Shi Mingqin M   Huang Xiaoyi X   Wei Yuanyuan Y   Li Tao T   Zhang Xiaoyu X   Xie Zhaohu Z   Wang Na N   Qin Dongdong D   Li Zhaofu Z  

Frontiers in genetics 20230405


<b>Objective:</b> To observe the clinical efficacy and safety of Yiqi Yangxue formula (YQYXF) on knee osteoarthritis (KOA), and to explore the underlying therapeutic mechanism of YQYXF through endogenous differential metabolites and their related metabolic pathways. <b>Methods:</b> A total of 61 KOA patients were recruited and divided into the treatment group (YQYXF, 30 cases) and the control group (celecoxib, Cxb, 31 cases). Effects of these two drugs on joint pain, swelling, erythrocyte sedime  ...[more]

Similar Datasets

2018-06-11 | E-MTAB-6864 | biostudies-arrayexpress
2018-11-05 | GSE99662 | GEO
2024-09-13 | GSE246252 | GEO
2020-11-17 | PXD014666 | Pride
2024-09-02 | BIOMD0000000928 | BioModels
2022-05-16 | GSE200522 | GEO
2020-05-25 | PXD016842 | Pride
2022-05-19 | PXD029116 | Pride
2023-02-07 | PXD029434 | Pride
2020-09-18 | GSE158106 | GEO